Article

Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996-2004.

National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
The American journal of tropical medicine and hygiene (Impact Factor: 2.74). 09/2006; 75(2):333-6.
Source: PubMed

ABSTRACT During 1996 through 2004, 29 cases of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) have been reported worldwide; 17 were fatal. Stress-dose corticosteroid (SDS) therapy has recently been found to improve survival among patients with septic shock but benefit for the treatment of YEL-AVD patients in septic shock is unknown. We retrospectively reviewed medical records of 11 U.S. YEL-AVD cases reported to the Vaccine Adverse Event Reporting System (VAERS) from 1996 through 2004. Four of 11 case-patients received SDS; 3 of these 4 (75%) survived. Seven patients did not receive SDS and 2 (29%) survived. Altered mental status was documented on admission for 5 of the 11 patients; 4 of these 5 did not receive SDS and died, whereas one received SDS and survived. The use of stress-dose steroids might be a factor that influenced the survival of these YEL-AVD patients and should be further evaluated in the management of both YEL-AVD and wild-type yellow fever septic shock.

0 Followers
 · 
92 Views
  • Source
    • "The virus is endemic in tropical areas of Africa and Latin America, with a combined population of over 900 million people [8] [9]. Although a highly effective and safe vaccine (17D) is available [10], many people do not get vaccinated, primarily because a cold chain is needed for this live-attenuated vaccine. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Several flaviviruses, such as the yellow fever virus and the dengue virus cause severe and potentially lethal infection in man. Following up on our initial hit 3',5'-bistritylated uridine 1, a series of alkylated nucleoside analogues were synthesized and evaluated for their in vitro antiviral activities against dengue fever virus and yellow fever virus. Hereto, alkyl and aryl groups were attached at various positions of the sugar ring combined with subtle variation of the heterocyclic base. Among the new series of derivatives, 3',5'-di-O-trityl-5-fluoro-2'-deoxyuridine (39) was the most efficient in this series and inhibited both yellow fever virus and dengue virus replication with a 50% effective concentration (EC50) of ∼1 μg/mL without considerable cytotoxicity. The other fluorinated derivatives proved more toxic. Almost all diphenylmethylated pyrimidine nucleosides with 3',5'-di-O-benzhydryl-2'-deoxyuridine (50) as the example were endowed with strong cytotoxic effects down to 1 μg/mL.
    European Journal of Medicinal Chemistry 02/2014; 76C:98-109. DOI:10.1016/j.ejmech.2014.02.011 · 3.43 Impact Factor
  • Source
    • "The virus is endemic in tropical areas of Africa and Latin America, with a combined population of over 900 million people [8] [9]. Although a highly effective and safe vaccine (17D) is available [10], many people do not get vaccinated, primarily because a cold chain is needed for this live-attenuated vaccine. "
    Article: Reply:
    Hepatology 11/2009; 51(1):345. DOI:10.1002/hep.23414 · 11.19 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Yellow fever continues to occur in regions of Africa and South America, despite the availability of effective vaccines. Recently, some cases of severe neurologic disease and multiorgan system disease have been described in individuals who received yellow fever vaccine. These events have focused attention on the need to define criteria for judicious use of yellow fever vaccine and to describe the spectrum of adverse events that may be associated with yellow fever vaccine. Describing host factors that would increase risk of these events and identifying potential treatment modalities for yellow fever and yellow fever vaccine-associated adverse events are subjects of intense investigation.
    Clinical Infectious Diseases 04/2007; 44(6):850-6. DOI:10.1086/511869 · 9.42 Impact Factor
Show more